Dan Barouch
#61,389
Most Influential Person Now
Researcher
Dan Barouch's AcademicInfluence.com Rankings
Dan Barouchbiology Degrees
Biology
#2841
World Rank
#4443
Historical Rank
Immunology
#152
World Rank
#160
Historical Rank
Dan Barouchphilosophy Degrees
Philosophy
#4224
World Rank
#6668
Historical Rank
Logic
#1729
World Rank
#2564
Historical Rank
Download Badge
Biology Philosophy
Dan Barouch's Degrees
- Doctorate Medicine Harvard University
Why Is Dan Barouch Influential?
(Suggest an Edit or Addition)According to Wikipedia, Dan Hung Barouch is an American physician, immunologist, and virologist. He is known for his work on the pathogenesis and immunology of viral infections and the development of vaccine strategies for global infectious diseases.
Dan Barouch's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Phenotypic Analysis of Antigen-Specific T Lymphocytes (1996) (3961)
- An immunogenic personal neoantigen vaccine for patients with melanoma (2017) (1820)
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 (2021) (1283)
- Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. (2000) (951)
- DNA vaccine protection against SARS-CoV-2 in rhesus macaques (2020) (931)
- Potently neutralizing and protective human antibodies against SARS-CoV-2 (2020) (824)
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine (2021) (813)
- Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques (2020) (812)
- SARS-CoV-2 infection protects against rechallenge in rhesus macaques (2020) (779)
- Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes (2002) (740)
- Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques (2020) (736)
- Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer (2008) (631)
- Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys (2013) (610)
- Animal models for COVID-19 (2020) (582)
- Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus Monkeys (2014) (507)
- Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity (2006) (499)
- Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys (2008) (498)
- Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients (2020) (496)
- Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys (2011) (481)
- Vaccine Protection Against Zika Virus from Brazil (2016) (464)
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D (2007) (460)
- Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys (2016) (445)
- Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 (2004) (394)
- Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 (2005) (376)
- A Blueprint for HIV Vaccine Discovery. (2012) (372)
- International AIDS Society global scientific strategy: towards an HIV cure 2016 (2016) (372)
- Mosaic HIV-1 Vaccines Expand the Breadth and Depth of Cellular Immune Responses in Rhesus Monkeys (2010) (371)
- Challenges in the development of an HIV-1 vaccine (2008) (368)
- Rapid development of a DNA vaccine for Zika virus (2016) (340)
- Analysis of Gag-specific Cytotoxic T Lymphocytes in Simian Immunodeficiency Virus–infected Rhesus Monkeys by Cell Staining with a Tetrameric Major Histocompatibility Complex Class I–Peptide Complex (1998) (323)
- Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys (2013) (312)
- Distinct Early Serological Signatures Track with SARS-CoV-2 Survival (2020) (303)
- Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 (2021) (287)
- Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology (2015) (286)
- Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys (2015) (275)
- Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 (2022) (264)
- International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. (2011) (257)
- Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters (2020) (257)
- Pathogenic Simian Immunodeficiency Virus Infection Is Associated with Expansion of the Enteric Virome (2012) (257)
- Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. (2021) (243)
- Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic (2020) (242)
- Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches (2017) (236)
- Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans (2021) (232)
- Polymer multilayer tattooing for enhanced DNA vaccination. (2013) (229)
- Antigen-specific NK cell memory in rhesus macaques (2015) (224)
- Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys (2016) (222)
- Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys (2018) (216)
- Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques (2017) (216)
- Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) (2018) (214)
- Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. (2021) (211)
- Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality (2020) (210)
- Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. (2000) (205)
- Immunologic strategies for HIV-1 remission and eradication (2014) (202)
- Prospects for vaccine protection against HIV-1 infection and AIDS. (2002) (201)
- Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants (2022) (200)
- Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor (2020) (199)
- Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination (2001) (197)
- Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron (2022) (197)
- Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses (2020) (193)
- Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. (2009) (189)
- Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors (2004) (180)
- Viral Escape from Dominant Simian Immunodeficiency Virus Epitope-Specific Cytotoxic T Lymphocytes in DNA-Vaccinated Rhesus Monkeys (2003) (177)
- Potent CD4+ T Cell Responses Elicited by a Bicistronic HIV-1 DNA Vaccine Expressing gp120 and GM-CSF1 (2002) (175)
- Adenovirus vector-based vaccines for human immunodeficiency virus type 1. (2005) (171)
- Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity (2005) (170)
- HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120 (2012) (169)
- Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma (2021) (168)
- Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys (2017) (167)
- Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. (1998) (163)
- Generation of Effector Memory T Cell–Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination (2013) (161)
- A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates (2005) (159)
- First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). (2013) (155)
- Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines (2021) (154)
- Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques (2020) (149)
- Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. (1995) (148)
- Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials (2017) (148)
- Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates (2005) (146)
- Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination (2021) (142)
- Dynamics and significance of the antibody response to SARS-CoV-2 infection (2020) (138)
- Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection (2016) (136)
- Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys (2008) (136)
- Adenovirus Serotype 5 Neutralizing Antibodies Target both Hexon and Fiber following Vaccination and Natural Infection (2011) (130)
- Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. (2004) (129)
- Recruitment of Antigen-Presenting Cells to the Site of Inoculation and Augmentation of Human Immunodeficiency Virus Type 1 DNA Vaccine Immunogenicity by In Vivo Electroporation (2008) (126)
- Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor (2020) (125)
- Low-Dose Mucosal Simian Immunodeficiency Virus Infection Restricts Early Replication Kinetics and Transmitted Virus Variants in Rhesus Monkeys (2010) (125)
- Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles (2017) (123)
- Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines (2003) (122)
- Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus (2016) (121)
- Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques (2017) (121)
- Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. (2019) (120)
- HLA-A2 subtypes are functionally distinct in peptide binding and presentation (1995) (120)
- Fitness Costs Limit Viral Escape from Cytotoxic T Lymphocytes at a Structurally Constrained Epitope (2004) (120)
- Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers (2019) (118)
- Novel adenovirus vector-based vaccines for HIV-1 (2010) (118)
- Vaccination with Adenovirus Serotypes 35, 26, and 48 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys (2012) (115)
- Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan Africa (2006) (114)
- Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys (2016) (114)
- Initiation of Antiviral B Cell Immunity Relies on Innate Signals from Spatially Positioned NKT Cells (2017) (114)
- HIV-1 vaccine development after STEP. (2010) (112)
- Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). (2013) (109)
- Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters (2022) (109)
- Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination (2016) (109)
- Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail (2017) (105)
- Breadth of Neutralizing Antibodies Elicited by Stable, Homogeneous Clade A and Clade C HIV-1 gp140 Envelope Trimers in Guinea Pigs (2010) (104)
- Durability and correlates of vaccine protection against Zika virus in rhesus monkeys (2017) (102)
- Simian-Human Immunodeficiency Virus Escape from Cytotoxic T-Lymphocyte Recognition at a Structurally Constrained Epitope (2003) (101)
- The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses (2004) (101)
- Zika virus vaccines (2018) (96)
- Interactions among the major and minor coat proteins of polyomavirus (1994) (94)
- Covid-19 Vaccines — Immunity, Variants, Boosters (2022) (94)
- Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus Monkeys (2001) (92)
- Novel approaches for vaccine development (2021) (91)
- VirusSeeker, a computational pipeline for virus discovery and virome composition analysis. (2017) (91)
- Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge (2017) (90)
- Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus Monkeys (2005) (90)
- Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys (2018) (90)
- Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. (2006) (89)
- A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. (2015) (89)
- Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans (2009) (88)
- Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques (2018) (86)
- Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. (2006) (86)
- Hyperexpansion of RNA Bacteriophage Diversity (2016) (85)
- Alternative Serotype Adenovirus Vaccine Vectors Elicit Memory T Cells with Enhanced Anamnestic Capacity Compared to Ad5 Vectors (2012) (85)
- Approaches and Challenges in SARS-CoV-2 Vaccine Development (2020) (84)
- Prospects for a Zika Virus Vaccine (2017) (83)
- Adenovirus Serotype 5-Specific Neutralizing Antibodies Target Multiple Hexon Hypervariable Regions (2011) (83)
- Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S (2022) (83)
- Trafficking of Antigen-Specific CD8+ T Lymphocytes to Mucosal Surfaces following Intramuscular Vaccination1 (2008) (81)
- A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys (2008) (81)
- Vaccine delivery with microneedle skin patches in nonhuman primates (2013) (80)
- Comparative Characterization of Transfection- and Infection-Derived Simian Immunodeficiency Virus Challenge Stocks for In Vivo Nonhuman Primate Studies (2013) (78)
- Broadly Neutralizing Antibodies for HIV Eradication (2016) (78)
- Recruitment of different subsets of antigen‐presenting cells selectively modulates DNA vaccine‐elicited CD4+ and CD8+ T lymphocyte responses (2004) (77)
- Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial (2020) (77)
- Rational design of gene‐based vaccines (2006) (77)
- Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8+ T Cells Induced by Different Adenovirus Vectors (2012) (77)
- Multiple Innate Immune Pathways Contribute to the Immunogenicity of Recombinant Adenovirus Vaccine Vectors (2010) (75)
- Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafficking of Vaccine-Elicited CD8+ T Lymphocytes (2010) (73)
- Discrete SARS-CoV-2 antibody titers track with functional humoral stability (2021) (73)
- HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (72)
- SIV Infection-Mediated Changes in Gastrointestinal Bacterial Microbiome and Virome Are Associated with Immunodeficiency and Prevented by Vaccination. (2016) (72)
- New concepts in HIV-1 vaccine development. (2016) (71)
- DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. (2003) (71)
- Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity (2006) (70)
- Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants (2005) (70)
- Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques (2021) (69)
- A global approach to HIV-1 vaccine development (2013) (69)
- Vitamin A Deficiency Impairs Vaccine-Elicited Gastrointestinal Immunity (2011) (69)
- Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection (2015) (67)
- Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement (2018) (67)
- Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. (2016) (66)
- The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys (2013) (66)
- Modulation of DNA Vaccine-Elicited CD8+ T-Lymphocyte Epitope Immunodominance Hierarchies (2006) (66)
- Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs (2021) (66)
- Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors (2018) (66)
- Systems serology for evaluation of HIV vaccine trials (2017) (65)
- Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections (2018) (65)
- Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. (2004) (65)
- Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. (2015) (65)
- Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies (2014) (64)
- Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays (2021) (63)
- Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses (2020) (62)
- Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection (2010) (62)
- Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies (2003) (60)
- Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial (2016) (60)
- CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. (2001) (59)
- Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. (2017) (59)
- Defining the risk of SARS-CoV-2 variants on immune protection (2022) (58)
- Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. (2012) (57)
- The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections. (2019) (56)
- Novel vaccine vectors for HIV-1 (2017) (55)
- Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial. (2022) (55)
- A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. (2019) (55)
- BK virus-associated hemorrhagic cystitis in a Human Immunodeficiency Virus-infected patient. (2002) (54)
- HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge (2019) (54)
- Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. (2008) (53)
- mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions (2022) (53)
- Contributions of Mamu-A*01 Status and TRIM5 Allele Expression, But Not CCL3L Copy Number Variation, to the Control of SIVmac251 Replication in Indian-Origin Rhesus Monkeys (2010) (52)
- Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy (2018) (50)
- Late Endosomal Trafficking of Alternative Serotype Adenovirus Vaccine Vectors Augments Antiviral Innate Immunity (2014) (50)
- Disseminated Trichosporonosis Caused by Trichosporon loubieri (2003) (49)
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine (2021) (48)
- Gag-Specific Cellular Immunity Determines In Vitro Viral Inhibition and In Vivo Virologic Control following Simian Immunodeficiency Virus Challenges of Vaccinated Rhesus Monkeys (2012) (47)
- Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. (2020) (47)
- T cell immunity to COVID-19 vaccines (2022) (46)
- Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors (2014) (46)
- Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission (2012) (46)
- Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys (2012) (46)
- Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. (2009) (45)
- Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques (2016) (44)
- NS1 DNA vaccination protects against Zika infection through T cell–mediated immunity in immunocompetent mice (2019) (44)
- Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP (2021) (44)
- Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice (2021) (44)
- Vaccine Protection Against Functional CTL Abnormalities in Simian Human Immunodeficiency Virus-Infected Rhesus Monkeys1 (2002) (44)
- HLA Class I Binding Motifs Derived from Random Peptide Libraries Differ at the COOH Terminus from Those of Eluted Peptides (1997) (44)
- Viral evolution and challenges in the development of HIV vaccines. (2002) (43)
- Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge (2018) (43)
- Programmed Cell Death 1 and Helios Distinguish TCR-αβ+ Double-Negative (CD4−CD8−) T Cells That Derive from Self-Reactive CD8 T Cells (2015) (42)
- Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques. (2019) (42)
- Protective Efficacy of a Single Immunization of a Chimeric Adenovirus Vector-Based Vaccine against Simian Immunodeficiency Virus Challenge in Rhesus Monkeys (2009) (41)
- Novel vaccine vectors for HIV-1 (2014) (41)
- Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor (2020) (40)
- Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys (2017) (40)
- Durable Mucosal Simian Immunodeficiency Virus-Specific Effector Memory T Lymphocyte Responses Elicited by Recombinant Adenovirus Vectors in Rhesus Monkeys (2011) (40)
- GagPol-specific CD4+ T-cells increase the antibody response to Env by intrastructural help (2013) (40)
- Characterization of immune responses in fully vaccinated individuals following breakthrough infection with the SARS-CoV-2 delta variant (2022) (39)
- Nonreplicating vectors in HIV vaccines. (2013) (39)
- A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component (2014) (39)
- Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. (2001) (38)
- Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells (2016) (38)
- Magnitude and Diversity of Cytotoxic-T-Lymphocyte Responses Elicited by Multiepitope DNA Vaccination in Rhesus Monkeys (2003) (38)
- Differential Antigen Requirements for Protection against Systemic and Intranasal Vaccinia Virus Challenges in Mice (2008) (37)
- Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease (2021) (37)
- Therapeutic and Protective Efficacy of a Dengue Antibody Against Zika Infection in Rhesus Monkeys (2018) (37)
- Design of Lipid Nanocapsule Delivery Vehicles for Multivalent Display of Recombinant Env Trimers in HIV Vaccination (2014) (37)
- Advances and gaps in SARS-CoV-2 infection models (2022) (37)
- Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques (2021) (36)
- Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. (2015) (36)
- Intestinal Stromal Tumors in a Simian Immunodeficiency Virus-infected, Simian Retrovirus-2 Negative Rhesus Macaque (Macaca mulatta) (2005) (36)
- DNA Vaccination for HIV-1 and SIV (2001) (35)
- CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells (2015) (35)
- Mucosal Trafficking of Vector-Specific CD4+ T Lymphocytes following Vaccination of Rhesus Monkeys with Adenovirus Serotype 5 (2010) (35)
- Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics (2020) (35)
- Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption (2020) (34)
- Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys (2017) (34)
- An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice (2021) (34)
- Immune Correlate-Guided HIV Vaccine Design. (2018) (34)
- Structural constraints on viral escape from HIV- and SIV-specific cytotoxic T-lymphocytes. (2004) (34)
- Functional Equivalency of B7-1 and B7-2 for Costimulating Plasmid DNA Vaccine-Elicited CTL Responses1 (2000) (34)
- Robust Vaccine-Elicited Cellular Immune Responses in Breast Milk following Systemic Simian Immunodeficiency Virus DNA Prime and Live Virus Vector Boost Vaccination of Lactating Rhesus Monkeys (2010) (33)
- HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design (2019) (33)
- Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. (2004) (33)
- Dysfunction of Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus-Induced IL-2 Expression by Central Memory CD4+ T Lymphocytes1 (2005) (32)
- Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera (2021) (32)
- First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1 (2018) (31)
- Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron Variant (2022) (31)
- Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. (2014) (31)
- Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer (2014) (31)
- Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques (2021) (30)
- Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV (2018) (30)
- B7 co‐stimulatory requirements differ for induction of immune responses by DNA, protein and recombinant pox virus vaccination (2000) (30)
- Mosaic HIV-1 Gag Antigens Can Be Processed and Presented to Human HIV-Specific CD8+ T Cells (2011) (30)
- First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector (2018) (29)
- TLR4 Ligands Augment Antigen-Specific CD8+ T Lymphocyte Responses Elicited by a Viral Vaccine Vector (2010) (29)
- Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters (2022) (29)
- Feasibility and safety of ultrasound-guided minimally invasive autopsy in COVID-19 patients (2020) (28)
- CMV Primes Functional Alternative Signaling in Adaptive Δg NK Cells but Is Subverted by Lentivirus Infection in Rhesus Macaques (2018) (28)
- Global Dysfunction of CD4 T-Lymphocyte Cytokine Expression in Simian-Human Immunodeficiency Virus/SIV-Infected Monkeys Is Prevented by Vaccination (2003) (28)
- Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants (2022) (28)
- The Number of Toll-Like Receptor 9-Agonist Motifs in the Adenovirus Genome Correlates with Induction of Dendritic Cell Maturation by Adenovirus Immune Complexes (2012) (27)
- Longitudinal Requirement for CD4+ T Cell Help for Adenovirus Vector–Elicited CD8+ T Cell Responses (2014) (27)
- Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern (2021) (27)
- Generation and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks (2014) (27)
- Response to Comment on “Trafficking of Antigen-Specific CD8+ T Lymphocytes to Mucosal Surfaces following Intramuscular Vaccination” (2009) (27)
- First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002). (2014) (26)
- CD8 T Cells Contribute to Vaccine Protection Against SARS-CoV-2 in Macaques (2022) (26)
- Vaccine protection against the SARS-CoV-2 Omicron variant in macaques (2022) (26)
- COVID-19 Vaccines: Adenoviral Vectors. (2021) (25)
- A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine (2014) (25)
- Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study (2020) (25)
- HIV-1 vaccine development: Progress and prospects (2007) (25)
- Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study (2022) (25)
- Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques (2021) (25)
- Neutralizing antibodies for HIV-1 prevention. (2019) (25)
- Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors (2018) (24)
- Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. (2011) (24)
- Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques (2019) (24)
- Prior Vaccination Increases the Epitopic Breadth of the Cytotoxic T-Lymphocyte Response That Evolves in Rhesus Monkeys following a Simian-Human Immunodeficiency Virus Infection (2002) (23)
- Comorbid illnesses are associated with altered adaptive immune responses to SARS-CoV-2 (2021) (23)
- HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines? (2004) (23)
- Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention (2021) (22)
- Cytokine-induced augmentation of DNA vaccine-elicited SIV-specific immunity in rhesus monkeys. (2000) (22)
- Challenges in the Search for an HIV Vaccine (2003) (22)
- A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials (2019) (22)
- A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine (2021) (22)
- Immunogenicity of recombinant Modified Vaccinia Ankara following a single or multi-dose vaccine regimen in rhesus monkeys. (2009) (22)
- Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts (2021) (21)
- Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques (2022) (21)
- Translational Mini‐Review Series on Vaccines for HIV: T lymphocyte trafficking and vaccine‐elicited mucosal immunity (2009) (21)
- Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized Mice (2018) (20)
- An IL-2/Ig fusion protein influences CD4+ T lymphocytes in naive and simian immunodeficiency virus-infected Rhesus monkeys. (2001) (20)
- Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma (2018) (20)
- RAPID CHARACTERIZATION OF HLA CLASS I ALLELES BY GENE MAPPING USING ARMS PCR (1995) (20)
- Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19 (2021) (20)
- Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences (2016) (20)
- Evolution of the innate and adaptive immune response in women with acute Zika virus infection (2019) (20)
- Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques (2021) (19)
- Adenovirus serotype 5 vaccine vectors trigger IL-27–dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function (2016) (19)
- The quest for an HIV-1 vaccine--moving forward. (2013) (19)
- Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. (2012) (18)
- Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials. (2012) (18)
- Neutralization Escape by the SARS-CoV-2 Omicron Variants BA.2.12.1 and BA.4/BA.5 (2022) (18)
- Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR-/- Mice. (2019) (18)
- Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1 (2023) (18)
- Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19 (2021) (18)
- Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection (2021) (18)
- Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial (2020) (17)
- Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial (2021) (17)
- Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters (2021) (17)
- SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques (2021) (17)
- Durability of Heterologous and Homologous COVID-19 Vaccine Boosts (2022) (17)
- TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption (2021) (17)
- Accelerating HIV-1 Vaccine Efficacy Trials (2014) (17)
- Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6 (2022) (16)
- Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). (2020) (16)
- Hexon Hypervariable Region-Modified Adenovirus Type 5 (Ad5) Vectors Display Reduced Hepatotoxicity but Induce T Lymphocyte Phenotypes Similar to Ad5 Vectors (2014) (16)
- Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization (2016) (16)
- Translational Mini‐Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development (2009) (16)
- Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. (2020) (16)
- Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy (2016) (16)
- Co-infection with coronavirus disease 2019, previously undiagnosed human immunodeficiency virus, Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonitis, with possible immune reconstitution inflammatory syndrome (2021) (16)
- Hepatitis C Genotype 1 Mosaic Vaccines Are Immunogenic in Mice and Induce Stronger T-Cell Responses than Natural Strains (2012) (16)
- Statoviruses, A novel taxon of RNA viruses present in the gastrointestinal tracts of diverse mammals (2017) (16)
- Regulation of CD4 T cells and their effects on immunopathological inflammation following viral infection (2017) (15)
- Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines (2020) (15)
- Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19 (2021) (15)
- HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. (2020) (15)
- Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation (2020) (15)
- Broadly neutralizing antibodies for HIV-1 prevention and therapy. (2021) (14)
- Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens. (2017) (14)
- Transient CD4+ T Cell Depletion Results in Delayed Development of Functional Vaccine-Elicited Antibody Responses (2016) (14)
- Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques (2020) (13)
- Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection (2021) (13)
- Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96. (2011) (13)
- A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates (2021) (13)
- SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques (2022) (13)
- Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles (2021) (13)
- Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy (2018) (12)
- Correction: Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination (2016) (12)
- The immune space: a concept and template for rationalizing vaccine development. (2014) (12)
- Use of Molecular Beacons for Rapid, Real-Time, Quantitative Monitoring of Cytotoxic T-Lymphocyte Epitope Mutations in Simian Immunodeficiency Virus (2005) (12)
- Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys (2018) (12)
- Accelerated Heterologous Adenovirus Prime-Boost SIV Vaccine in Neonatal Rhesus Monkeys (2012) (12)
- Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1 (2022) (12)
- Augmented Replicative Capacity of the Boosting Antigen Improves the Protective Efficacy of Heterologous Prime-Boost Vaccine Regimens (2014) (12)
- Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity (2022) (12)
- Epidemiological and immunological features of obesity and SARS-CoV-2 (2020) (11)
- Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys (2018) (11)
- Natural killer cell immunosuppressive function requires CXCR3-dependent redistribution within lymphoid tissues (2021) (11)
- Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys (2017) (11)
- Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants (2021) (10)
- Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2 (2021) (10)
- Viral rebound kinetics following single and combination immunotherapy for HIV/SIV (2019) (10)
- Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial (2022) (10)
- HIV Molecular Immunology 2014 (2015) (10)
- A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. (1995) (9)
- Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial (2019) (9)
- Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors (2018) (9)
- The sooner the better: innate immunity as a path toward the HIV cure. (2016) (9)
- A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques (2022) (9)
- Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers (2019) (9)
- A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques (2022) (9)
- A step forward for HIV vaccines. (2018) (9)
- Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques (2021) (9)
- Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization (2015) (9)
- A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli (2019) (9)
- Vaccine nanodiscs plus polyICLC elicit robust CD8+ T cell responses in mice and non-human primates. (2021) (9)
- Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity (2021) (9)
- The Global Fund to Fight AIDS, Tuberculosis and Malaria: funding for unpopular public-health programmes (2004) (9)
- Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs (2018) (9)
- Engagement of a T cell receptor by major histocompatibility complex irrespective of peptide (1997) (9)
- T cell and antibody functional correlates of severe COVID-19 (2020) (9)
- HIV Molecular Immunology 2015 (2016) (9)
- An Attenuated Listeria monocytogenes Vector Primes More Potent Simian Immunodeficiency Virus-Specific Mucosal Immunity than DNA Vaccines in Mice (2013) (8)
- Zika virus dynamics: Effects of inoculum dose, the innate immune response and viral interference (2021) (8)
- Effectiveness of the Ad26.Cov2.S Vaccine in Health Care Workers in South Africa (2021) (8)
- Immunogenicity of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques (2020) (8)
- Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters (2023) (8)
- Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates (2022) (8)
- Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition (2022) (8)
- A critical role for the adenovirus serotype 5 hexon in liver gene transfer (2008) (7)
- Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics (2021) (7)
- Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters (2023) (7)
- Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivo (2019) (7)
- Origin of rebound virus in chronically SIV-infected Rhesus monkeys following treatment discontinuation (2020) (7)
- Natural Evolution of Broadly Neutralizing Antibodies (2015) (6)
- Adenovirus Serotype 26 and 35 Vectors Induce Simian Immunodeficiency Virus-Specific T Lymphocyte Responses in Foreskin in Rhesus Monkeys (2014) (6)
- SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques (2021) (6)
- Protective efficacy of an attenuated Mtb ΔLprG vaccine in mice (2020) (6)
- HIV-1 vaccine candidate ineffective. (2007) (6)
- HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys (2022) (6)
- mRNA Vaccines Induce Rapid Antibody Responses in Mice (2021) (6)
- Long-acting capsid inhibitor protects macaques from repeat SHIV challenges (2021) (6)
- Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice (2021) (5)
- IL-10 driven memory T cell survival and Tfh differentiation promote HIV persistence (2021) (5)
- Adenovirus Vector Vaccination Impacts NK Cell Rheostat Function following Lymphocytic Choriomeningitis Virus Infection (2018) (5)
- Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates (2021) (5)
- Coronavirus Disease 2019 Messenger RNA Vaccine Immunogenicity in Immunosuppressed Individuals (2021) (5)
- Serological Markers of SARS-CoV-2 Reinfection (2022) (5)
- Increased IL-6 expression precedes reliable viral detection in the rhesus macaque brain during acute SIV infection (2021) (5)
- Common Features of Mucosal and Peripheral Antibody Responses Elicited by Candidate HIV-1 Vaccines in Rhesus Monkeys (2014) (5)
- Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C (2020) (5)
- Clinical development and approval of COVID-19 vaccines (2022) (5)
- Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques (2021) (4)
- Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika‐specific antibodies (2020) (4)
- Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2 (2021) (4)
- Delineation and Modulation of the Natural Killer Cell Transcriptome in Rhesus Macaques During ZIKV and SIV Infections (2020) (4)
- A Modular Biomaterial Scaffold‐Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS‐CoV‐2 Antigens (2021) (4)
- mRNA vaccines induce rapid antibody responses in mice (2022) (4)
- Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques (2021) (4)
- Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing (2021) (4)
- Rapid Loss of CD4 T Cells by Pyroptosis during Acute SIV Infection in Rhesus Macaques (2022) (4)
- Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2 (2021) (4)
- Plasma Proteomics of COVID-19–Associated Cardiovascular Complications (2022) (3)
- mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant (2022) (3)
- Young and Early Career Investigators: Report from a Global HIV Vaccine Enterprise Working Group (2010) (3)
- A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques (2022) (3)
- Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial (2022) (3)
- Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection (2020) (3)
- CD32 does not mark the HIV-1/SIV latent reservoir (2017) (3)
- SARS-CoV-2 seroprevalence, cumulative infections, and immunity to symptomatic infection – A multistage national household survey and modelling study, Dominican Republic, June–October 2021 (2022) (3)
- Vaccine-induced protection from homologous Tier 2 simian-human immunodeficiency virus challenge in nonhuman primates (2018) (3)
- Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies (2022) (3)
- An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice (2021) (3)
- Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice (2022) (3)
- Epidemiological and Immunological Features of Obesity and SARS-CoV-2 (2021) (3)
- HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120 (2012) (3)
- Multiplexed proteomics and imaging of resolving and lethal SARS-CoV-2 infection in the lung (2020) (3)
- Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial (2021) (3)
- Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial (2022) (3)
- Hexon Hypervariable Region-Modified Adenovirus 5 Vectors Display Reduced (2014) (2)
- Characterization of a novel HLA-A2 variant, A*0214, by ARMS-PCR and DNA sequencing (2004) (2)
- Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS (2021) (2)
- Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques (2022) (2)
- Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters (2022) (2)
- Reduced airborne transmission of SARS-CoV-2 BA.1 Omicron virus in Syrian hamsters (2022) (2)
- Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention (2022) (2)
- HIV vaccine trial canceled. (2008) (2)
- Integrated technology platform for accelerated discovery of antiviral antibody therapeutics (2020) (2)
- A rapidly adaptable biomaterial vaccine for SARS-CoV-2 (2020) (2)
- T‐cell subset differentiation and antibody responses following antiretroviral therapy during simian immunodeficiency virus infection (2018) (1)
- Adenovirus 5 vaccination elicits IL-27, which impairs CD4 and CD8 T cell functionality (VAC12P.1113) (2015) (1)
- HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge (2019) (1)
- Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN (2022) (1)
- Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques (2023) (1)
- Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination (2021) (1)
- Abstracts of the 8th HIV Persistence during Therapy Workshop (2017) (1)
- Design of lipid nanoparticle delivery agents for multivalent display of recombinant Env trimers in HIV vaccination (2012) (1)
- Ad26.COV2.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques (2022) (1)
- Engineered microneedle arrays for transcutaneous HIV vaccine delivery (2012) (1)
- Power to Detect HIV Vaccine Effects in Repeated Low-Dose Challenge Experiments (2009) (1)
- Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir (2022) (1)
- 132 – Vaccines for Human Immunodeficiency Virus Type 1 Infection (2015) (1)
- Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys (2018) (1)
- Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (1)
- HIV-1 Latency by Transition. (2017) (1)
- Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human (2018) (1)
- COVID-19 prevention with subcutaneous administration of the monoclonal antibodies casirivimab and imdevimab: Subgroup analysis in participants with cardiovascular disease and diabetes (2021) (1)
- Correction: GagPol-specific CD4+ T-cells increase the antibody response to Env by intrastructural help (2013) (1)
- Selected modification of the adenovirus type 5 hexon modulates interaction with coagulation factor X and hepatocyte transduction in vivo (2009) (1)
- Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women (2022) (1)
- Vector induced skewing of antibody Fc-effector functions (2012) (1)
- Reduced SARS-CoV-2 disease outcomes in Syrian hamsters receiving immune sera: Quantitative image analysis in pathologic assessments (2022) (1)
- Models of SIV rebound after treatment interruption that involve multiple reactivation events (2020) (1)
- Identification of a novel HLA-A2 subtype, HLA-A*0216 (2004) (1)
- Virus Induced Lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics (2021) (1)
- Delay in viral rebound with TLR7 agonist, N6-LS and PGT121 in SHIV-infected macaques (2019) (1)
- Vaccines for Human Immunodeficiency Virus-1 Infection (2010) (1)
- 115 Immune Correlates of Protection in Rhesus Monkeys (2014) (0)
- The Promise of New Broadly Neutralizing Antibodies for the Prevention and Treatment of HIV (2015) (0)
- transfer serotype 5 hexon: effect of mutagenesis on FX interactions and gene Identification of coagulation factor (F)X binding sites on the adenovirus (2011) (0)
- Temporal regulation of adenovirus vector-elicited antibody responses by CD4 T cells (VAC4P.1111) (2015) (0)
- gp120 and GM-CSF Bicistronic HIV-1 DNA Vaccine Expressing T Cell Responses Elicited by a + Potent CD4 (2001) (0)
- Vaccine induced immunopathology mediated by memory CD4 T cells following chronic viral infection (VIR7P.1054) (2014) (0)
- A Novel CRISPR-Engineered, Stem Cell-Derived Cellular Vaccine (2021) (0)
- Rapid development of a DNAvaccine for Zika virus (2016) (0)
- Animal models for COVID-19 (2020) (0)
- Peptide microarrays for coverage of sequence diversity in monitoring the B cell immune response (TECH2P.911) (2015) (0)
- Making the paper: Dan Barouch (2008) (0)
- A genetically engineered, stem-cell-derived cellular vaccine (2022) (0)
- Plasmablast Phenotype and Mucosal Antibodies to V2 in Vaccine-induced Protection Against SIVmac251 (2014) (0)
- Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease (2021) (0)
- Experimental antibody plus TLR 7 agonist maintains viral suppression in monkeys (0)
- Pre-Existing Anti-Ad5 Immunity Serotype 35 Vaccine in the Presence of Immunogenicity of Recombinant Adenovirus (2004) (0)
- Spatial omics representation and functional tissue module inference using graph Fourier transform (2023) (0)
- Origin of rebound virus in chronically SIV-infected monkeys following treatment discontinuation (2019) (0)
- Therapeutic vaccination with Ad48/MVA and TLR7 stimulation in SIV-infected, ART-treated infant rhesus macaques (2020) (0)
- Abstract A53: Establishment of a brain tumor model with dysfunctional tumor immunity in mice as a platform for immunotherapeutic evaluation and PD-1 immunotherapy (2017) (0)
- Selective SARS-CoV2 BA.2 escape of antibody Fc/Fc-receptor interactions (2023) (0)
- Broadly Neutralizing Antibodies for HIV Eradication how this access benefits you. Your story matters (2016) (0)
- Tight regulation of memory CD4 T cells limits immunopathology following chronic viral infection (2016) (0)
- Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy (2018) (0)
- Broadly neutraliing antibody cocktail prevents the establishment of viral reservoir against a mixed SHIV challenge (2017) (0)
- Bovine adenovirus vectored vaccine for avian influenza. (2008) (0)
- Long-acting capsid inhibitor protects macaques from repeat SHIV challenges (2021) (0)
- Plasmid Cytokine/Ig Administration Responses to an HIV-1 DNA Vaccine by Augmentation and Suppression of Immune (1998) (0)
- Modeling the Effects of Mass Vaccination with CTL-Based AIDS Vaccines (2004) (0)
- A meta-analysis of passive immunization studies shows an association of serum neutralizing antibody titer with protection against SHIV challenge (2019) (0)
- Resource Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches Graphical Abstract Highlights (0)
- GagPol-specific CD4+T-cells increase the antibody response to Env by intrastructural help (2013) (0)
- 149 Novel Vectors and Antigens for a Next Generation HIV-1 Vaccine (2011) (0)
- Costimulating Plasmid DNA Vaccine-Elicited Functional Equivalency of B 7-1 and B 7-2 for Sharpe and (2000) (0)
- Adenovirus Serotype 5 Vectors Trigger IL-27-Dependent Inhibitory CD4+ T Cell Responses (2016) (0)
- Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys (2018) (0)
- Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice (2022) (0)
- The Future of Broadly Neutralizing Antibodies for HIV Eradication (2016) (0)
- A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL) (2020) (0)
- Universal mapping of humoral immune response using a versatile high-content and high-density peptide microarray (2012) (0)
- Route of Adenovirus-Based HIV-1 Vaccine Delivery Impacts the Phenotype and Trafficking of Vaccine-Elicited CD8 (cid:1) T Lymphocytes (cid:1) (2010) (0)
- Altered Cytokine Production in Human Intervillous Blood T Cells in Preeclampsia (2023) (0)
- Advances in HIV-1 Vaccine Volume II (2016) (0)
- Comparative Analysis of Simian Immunodeficiency Virus Gag-Specific Effector and Memory CD8 (cid:1) T Cells Induced by Different Adenovirus Vectors (2013) (0)
- Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques (2020) (0)
- Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor (2020) (0)
- Isolation of a rhesus calicivirus that can replicate in human cells. (2023) (0)
- A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines. (2023) (0)
- Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine (2021) (0)
- Evolution of the innate and adaptive immune response in women with acute Zika virus infection (2019) (0)
- Stability and neutralization capacity of a novel mosaic HIV-1 gp140 trimer in a guinea pig model (2012) (0)
- Ad26.COV2.S Prevents SARS-CoV-2 Induced Pathways of Inflammation and Thrombosis in Hamsters (2021) (0)
- Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (0)
- From the Blogosphere (2008) (0)
- Kinetics of gp41-specific antibody titers and contribution of Fc mediated gp41 specific antibody responses following SHIV-SF162P3 challenge. (2014) (0)
- Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption (2020) (0)
- Monkeys Immunodeficiency Virus-Infected Rhesus Abnormalities in Simian Human Vaccine Protection Against Functional CTL (2001) (0)
- Editorial Board (2016) (0)
- HIV Envelope vaccination elicits asparagine 332 glycan-dependent antibodies that resemble broadly neutralizing antibody precursors (2017) (0)
- Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate given via standard versus accelerated vaccination schedules: a phase 1, single-center, double-blind, sequential-group, randomized, placebo-controlled clinical trial (2020) (0)
- Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice (2023) (0)
- Vaccine-induced temporal cross-talk between myeloid cells reduces the risk of SIVmac251 acquisition (2017) (0)
- Design Optimization and Immune Kinetics of mRNA Vaccines (2022) (0)
- Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study. (2022) (0)
- Advances in HIV-1Vaccine Volume I (2016) (0)
- Augments Antiviral Innate Immunity Serotype Adenovirus Vaccine Vectors Late Endosomal Trafficking of Alternative (2014) (0)
- This information is current as Lactating Rhesus Monkeys and Live Virus Vector Boost Vaccination of Simian Immunodeficiency Virus DNA Prime Responses in Breast Milk following Systemic Robust Vaccine-Elicited Cellular Immune (2017) (0)
- Durable Mucosal Simian Immunodeficiency Virus-Specific Effector Memory T Lymphocyte Responses Elicited by Recombinant Adenovirus Vectors in Rhesus Monkeys (cid:1) (2011) (0)
- Gag-Specific Cellular Immunity Determines In Vitro Viral Inhibition and In 2 (2012) (0)
- Interactions amongtheMajorandMinorCoatProteins ofPolyomavirus (1994) (0)
- A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques (2021) (0)
- Subject Index Vol. 43, 2000 (2001) (0)
- T cell and antibody functional correlates of severe COVID-19 3 4 (2020) (0)
- THE HIV VACCINE PROBLEM : WHY HAVE PAST APPROACHES TO DEVELOP AN HIV VACCINE FAILED ? (0)
- Influenza and pertussis transplacental antibody transfer in women with and without preeclampsia (2020) (0)
- Editorial introductions. (2013) (0)
- Ad26.COV2.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques (2023) (0)
- Editorial Board (2016) (0)
- Generation and evaluation of simian-human immunodeficiency virus subtype AE challenge stocks (VIR2P.1166) (2015) (0)
- Ad5 but not Ad26 induces an IFN-γ+IL-10+ CD4+ T cell population following immunization (VAC12P.1023) (2014) (0)
- Protein Primarily against the Adenovirus Hexon Serotype 5 Vaccine Vectors Are Directed Neutralizing Antibodies to Adenovirus (2005) (0)
- HIV-Specific CD 8 Processed and Presented to Human Mosaic HIV-1 Gag Antigens Can Be (2011) (0)
- CD4 T cells control the induction, magnitude, and phenotype of the primary CD8 T cell response following adenovirus vector immunization (P4465) (2013) (0)
- Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants. (2023) (0)
- Blockade for Deeply Exhausted CD8 T Cells Augments the Rescue Potential of PD-L1 CD4 T Cell Depletion Substantially (2015) (0)
- B-107 Antibody-Based Vaccines and Therapeutics for HIV-1 (2014) (0)
- Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers (2014) (0)
- Phase 1 Clinical Trials of Two HIV-1 Vaccine Candidates (2006) (0)
- T Cells + HIV-Specific CD8 Processed and Presented to Human Mosaic HIV-1 Gag Antigens Can Be (2011) (0)
- B-105 Studies of Acute HIV Infection –Insights for Cure (2014) (0)
- Attenuated Mycobacterium tuberculosis Vaccine Protection in a Low Dose Murine Challenge Model (2023) (0)
- Contributors (2015) (0)
- Aberrant differentiation and exhaustion of adenovirus vaccine-elicited CD8 T cells primed in the absence of CD4 T cells (VAC3P.940) (2014) (0)
- HIV-1 diversity considerations for clinical studies of passively transferred broadly neutralising antibodies (2019) (0)
- Vaccine-Elicited Gastrointestinal Immunity Vitamin A Deficiency Impairs (2011) (0)
- Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex (2022) (0)
- Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics (2020) (0)
- Zika virus vaccines (2018) (0)
- 596. A Novel Replication Incompetent Human Subgroup D Adenoviral Vector Based on Type 49: Manufacture on PER.C6®, Cell Tropism and Immunogenicity (2006) (0)
- Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors (2018) (0)
- Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters (2020) (0)
- Publisher Correction: Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice (2023) (0)
- Combined HDAC and BET inhibition to enhance cancer vaccine-elicited T-cell responses. (2017) (0)
- Hyperexpansion of RNA Bacteriophage Diversity The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (2016) (0)
- Neutralizing Antibodies Afforded by Passive Infusion of Does Not Augment the Sterile Protection Immunodeficiency Virus DNA Vaccination Immunodeficiency Virus Type 1 / Simian Cellular Immunity Elicited by Human (2003) (0)
- TMOD-20. ESTABLISHMENT OF A BRAIN TUMOR MODEL WITH DYSFUNCTIONAL TUMOR IMMUNITY IN MICE AS A PLATFORM FOR IMMUNOTHERAPEUTIC EVALUATION (2016) (0)
- Erratum to: GagPol-specific CD4+T-cells increase the antibody response to Env by intrastructural help (2013) (0)
- Severely exhausted CD8 T cells are refractory to rescue by PD-1 blockade, but re-invigorate following concomitant CD4 T cell depletion in vivo (P6097) (2013) (0)
- 308: Altered decidua regulatory T cell proportion and phenotype in preeclampsia (2018) (0)
- Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques (2023) (0)
- Universal mapping of humoral immune response using a versatile high-content and high-density peptide microarray (2012) (0)
- Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters (2022) (0)
- Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys (2018) (0)
- LCMV-specific CD4 T cells induce immunopathology and impair immune protection following chronic LCMV infection (VIR1P.1132) (2015) (0)
- Progress in vaccine development for infectious diseases-a Keystone Symposia report. (2023) (0)
This paper list is powered by the following services:
Other Resources About Dan Barouch
What Schools Are Affiliated With Dan Barouch?
Dan Barouch is affiliated with the following schools:
